Epstein-Barr Virus peptide–major histocompatibility complex (EBV pMHC)

Epstein-Barr Virus (EBV) peptide–major histocompatibility complex (pMHC) refers to the presentation of EBV-derived antigenic peptides on the surface of host cells via MHC molecules. These complexes are critical for the immune system's ability to recognize and eliminate EBV-infected cells, as they serve as the primary ligands for T-cell receptors (TCRs) on CD8+ and CD4+ T cells (Source: PubMed, PMID: 31435312). In the context of EBV-associated malignancies, such as post-transplant lymphoproliferative disorder (PTLD) and nasopharyngeal carcinoma, these pMHC complexes are expressed on tumor cells, making them ideal targets for immunotherapy (Source: NIH, National Cancer Institute). Therapeutic strategies include adoptive T-cell therapies, such as tabelecleucel, and the development of TCR-like antibodies or bispecific T-cell engagers that specifically bind these viral epitopes (Source: EMA, Ebvallo Assessment Report). Targeting EBV pMHC allows for highly specific destruction of infected or malignant cells while sparing healthy, non-infected tissue. However, challenges include the high polymorphism of HLA molecules and the risk of off-target cross-reactivity with self-peptides (Source: Frontiers in Immunology, 2021).

Other names

EBV peptide-HLA complexEBV pHLAEpstein-Barr Virus antigen-MHC complexEBV-specific pMHC

Recognition by T-cell receptors (TCRs) or TCR-mimetic antibodies to trigger cytotoxic T-lymphocyte (CTL) mediated lysis of infected or malignant cells.